Akèy › Kansè Poumon ki pa ti selil › Kansas
Etid klinik pou Kansè Poumon ki pa ti selil nan Kansas
34 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan Kansas.
Vil nan Kansas
- Overland Park16 etid
- Kansas City11 etid
- Olathe7 etid
- Topeka7 etid
- Salina7 etid
- Hays6 etid
- Lawrence6 etid
- Wichita5 etid
Tèks ofisyèl etid la (Anglè)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- The University of Kansas Cancer Center - Olathe, Olathe
- Cancer Center of Kansas - Pratt, Pratt
- Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita
- ak 2 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT04267848A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
- Ascension Via Christi Hospitals Wichita, Wichita
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT07293247Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- HaysMed, Hays
- Lawrence Memorial Hospital, Lawrence
- The University of Kansas Cancer Center - Olathe, Olathe
- ak 2 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06498635Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
- Kansas City Cancer Center /ID# 273679, Overland Park
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT06772623Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
- The University of Kansas Cancer Center, Westwood
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT06881784A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
- University of Kansas Cancer Center, Westwood
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT05498428Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
- Research Site, Westwood
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06218914This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Saint Luke's South Hospital, Overland Park
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06758401A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- University of Kansas Cancer Center, Fairway
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06667076A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
- Research Site, Leawood
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06868277Pan-tumor MRD Study
- Cotton O'Neil Cancer Center [Stormont Vail], Topeka
- Cancer Center of Kansas, Wichita
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06605404Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- Central Care Cancer Center - Garden City, Garden City
- Central Care Cancer Center - Great Bend, Great Bend
- Mercy Hospital Pittsburg, Pittsburg
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT03191149A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- Cancer Center of Kansas, Wichita
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT06561386A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
- University of Kansas, Westwood
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07020117Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Local Institution - 007-942-B, Chanute
- Local Institution - 007-942-D, El Dorado
- Local Institution - 007-942-E, Independence
- ak 12 plis
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT04613596Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- University of Kansas Medical Center /ID# 263196, Westwood
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT06236438A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- The University of Kansas Cancer Center - Westwood, Westwood
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT06119581Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
- University of Kansas Medical Center, Kansas City
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT06343402Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
- University of Kansas Cancer Center, Kansas City
- University of Kansas Cancer Center-Overland Park, Overland Park
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT06500481A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- The University of Kansas Cancer Center, Kansas City
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 11, 2026 · NCT05592626Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- University of Kansas Medical Center (KUMC), Westwood
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 4, 2026 · NCT05579366A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- The University of Kansas Cancer Center, Investigational Drug Services, Fairway
- The University of Kansas Clinical Research Center, Fairway
- The University of Kansas Hospital, Kansas City
- ak 6 plis
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 6, 2026 · NCT04389632LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
- University of Kansas Cancer Center, Westwood
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Jun 25, 2026 · NCT06216301A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
- The University of Kansas Cancer Center, Westwood
Ap rekriteFaz 1/2
Laj 18 a 70 · Tout sèks · Mizajou Jun 11, 2026 · NCT05361174Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
- University of Kansas Clinical Research Center, Fairway
- HaysMed, Hays
- University of Kansas Cancer Center, Kansas City
- ak 7 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jun 3, 2026 · NCT05642572Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
- University of Kansas Clinical Research Center, Fairway
- HaysMed, Hays
- University of Kansas Cancer Center, Kansas City
- ak 7 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou May 6, 2026 · NCT06116682Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- University of Kansas Clinical Research Center, Fairway
- HaysMed, Hays
- University of Kansas Cancer Center, Kansas City
- ak 7 plis
Ap rekriteFaz 2
18 Minutes · Tout sèks · Mizajou May 5, 2026 · NCT06031688Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- University of Kansas Clinical Research Center, Fairway
- HaysMed, Hays
- University of Kansas Cancer Center, Kansas City
- ak 8 plis
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou May 5, 2026 · NCT06616584A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
- The University of Kansas Cancer Center, Fairway
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Mar 18, 2026 · NCT06244771Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- HaysMed, Hays
- Lawrence Memorial Hospital, Lawrence
- The University of Kansas Cancer Center - Olathe, Olathe
- ak 6 plis
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Mar 17, 2026 · NCT06418204Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC
- The University of Kansas Cancer Center (KUCC), Fairway
- The University of Kansas Cancer Center, Westwood Campus, Kansas City
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jan 28, 2026 · NCT04467723A Study of IBI363 in Subjects with Advanced Solid Malignancies
- University of Kansas Medical Center (KUMC), Fairway
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Dec 19, 2024 · NCT06281678Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients
- The University of Kansas Cancer Center, Westwood Campus, Kansas City
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou May 8, 2024 · NCT04680377Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC
- The University of Kansas Cancer Center (KUCC), Fairway
- The University of Kansas Cancer Center, Westwood Campus, Kansas City
Ap rekriteEtid obsèvasyon
Laj 18 a 110 · Tout sèks · Mizajou Feb 23, 2024 · NCT05332925Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.